Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment
- PMID: 38830401
- PMCID: PMC11560486
- DOI: 10.1016/j.chest.2024.04.031
Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment
Abstract
Background: Sarcoidosis staging primarily has relied on the Scadding chest radiographic system, although chest CT imaging is finding increased clinical use.
Research question: Whether standardized chest CT scan assessment provides additional understanding of lung function beyond Scadding stage and demographics is unknown and the focus of this study.
Study design and methods: We used National Heart, Lung, and Blood Institute study Genomics Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cases of sarcoidosis (n = 351) with Scadding stage and chest CT scans obtained in a standardized manner. One chest radiologist scored all CT scans with a visual scoring system, with a subset read by another chest radiologist. We compared demographic features, Scadding stage and CT scan findings, and the correlation between these measures. Associations between spirometry and diffusing capacity of the lungs for carbon monoxide (Dlco) results and CT scan findings and Scadding stage were determined using regression analysis (n = 318). Agreement between readers was evaluated using Cohen's κ value.
Results: CT scan features were inconsistent with Scadding stage in approximately 40% of cases. Most CT scan features assessed on visual scoring were associated negatively with lung function. Associations persisted for FEV1 and Dlco when adjusting for Scadding stage, although some CT scan feature associations with FVC became insignificant. Scadding stage was associated primarily with FEV1, and inclusion of CT scan features reduced significance in association between Scadding stage and lung function. Multivariable regression modeling to identify radiologic measures explaining lung function included Scadding stage for FEV1 and FEV1 to FVC ratio (P < .05) and marginally for Dlco (P < .15). Combinations of CT scan measures accounted for Scadding stage for FVC. Correlations among Scadding stage and CT scan features were noted. Agreement between readers was poor to moderate for presence or absence of CT scan features and poor for degree and location of abnormality.
Interpretation: In this study, CT scan features explained additional variability in lung function beyond Scadding stage, with some CT scan features obviating the associations between lung function and Scadding stage. Whether CT scan features, phenotypes, or endotypes could be useful for treating patients with sarcoidosis needs more study.
Keywords: Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS); Scadding stage; chest CT imaging; chest radiography; lung function; phenotypes; sarcoidosis.
Copyright © 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: L. A. M. has received grants from the National Institutes of Health [Grants R01HL140357, R01HL142049, R01HL136681], Ann Theodore Foundation, the Foundation for Sarcoidosis Research, Mallinckrodt Pharmaceuticals, and the University of Cincinnati [Mallinckrodt Pharmaceuticals Foundation Grant] and serves on the Scientific Advisory Board for the Foundation for Sarcoidosis Research and Boehringer Ingelheim. B. S. B. has received a grant from Mallinckrodt Pharmaceuticals. E. S. C. has received grants from the National Institutes of Health, the Foundation for Sarcoidosis Research, American Thoracic Society, serves on the Scientific Advisory Board for the Foundation for Sarcoidosis Research, and has participated in clinical trials sponsored by aTyr Pharma and LabCorp Drug. L. L. K. has received grants from the National Institutes of Health [Grant R01HL157533], An Theodore Foundation, and Mallinckrodt Pharmaceuticals. D. A. L. was coinvestigator on a grant from the National Institutes of Health [Grant R01HL142049] and served on a Scientific Advisory Board for Boehringer Ingelheim, Inc. N. K. is a scientific founder at Thyron; served as a consultant to Boehringer Ingelheim, Pliant, Astra Zeneca, RohBar, Veracyte, Augmanity, CSL Behring, Splisense, Galapagos, Fibrogen, GSK, Merck, and Thyron over the last 3 years; reports equity in Pliant and Thyron; reports grants from Veracyte, Boehringer Ingelheim, and BMS; and reports nonfinancial support from Astra Zeneca. None declared (W. L. L., I. C., G. K. B., E. M. B., W. P. D., E. H., K. G., S. R. W., C. F.).
Similar articles
-
Clinical phenotyping in sarcoidosis using cluster analysis.Respir Res. 2022 Apr 9;23(1):88. doi: 10.1186/s12931-022-01993-z. Respir Res. 2022. PMID: 35397561 Free PMC article.
-
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251336896. doi: 10.1177/17534666251336896. Epub 2025 May 8. Ther Adv Respir Dis. 2025. PMID: 40337907 Free PMC article.
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
The Association Between Air Pollution and Lung Function in Sarcoidosis and Implications for Health Disparities.Chest. 2025 Feb;167(2):507-517. doi: 10.1016/j.chest.2024.08.049. Epub 2024 Sep 17. Chest. 2025. PMID: 39299388
-
Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis.Cochrane Database Syst Rev. 2023 May 5;5(5):CD002011. doi: 10.1002/14651858.CD002011.pub3. Cochrane Database Syst Rev. 2023. PMID: 37144842 Free PMC article.
Cited by
-
The textures of sarcoidosis: quantifying lung disease through variograms.medRxiv [Preprint]. 2024 May 20:2024.05.20.24307618. doi: 10.1101/2024.05.20.24307618. medRxiv. 2024. Update in: Phys Med Biol. 2025 Jan 13;70(2). doi: 10.1088/1361-6560/ada19c. PMID: 38826353 Free PMC article. Updated. Preprint.
-
The textures of sarcoidosis: quantifying lung disease through variograms.Phys Med Biol. 2025 Jan 13;70(2):025004. doi: 10.1088/1361-6560/ada19c. Phys Med Biol. 2025. PMID: 39700622 Free PMC article.
References
-
- Drent M., Crouser E.D., Grunewald J. Challenges of Sarcoidosis and Its Management. N Engl J Med. 2021;385(11):1018–1032. - PubMed
-
- Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 pt 1):1885–1889. - PubMed
MeSH terms
Grants and funding
- U01 HL112694/HL/NHLBI NIH HHS/United States
- U01 HL112711/HL/NHLBI NIH HHS/United States
- R01 HL110883/HL/NHLBI NIH HHS/United States
- U01 HL112707/HL/NHLBI NIH HHS/United States
- U01 HL112702/HL/NHLBI NIH HHS/United States
- K24 HL127301/HL/NHLBI NIH HHS/United States
- U24 OH009077/OH/NIOSH CDC HHS/United States
- UL1 RR029882/RR/NCRR NIH HHS/United States
- T32 HL007085/HL/NHLBI NIH HHS/United States
- U01 HL112696/HL/NHLBI NIH HHS/United States
- U01 HL112712/HL/NHLBI NIH HHS/United States
- U01 HL137159/HL/NHLBI NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- U01 HL112708/HL/NHLBI NIH HHS/United States
- R01 HL127349/HL/NHLBI NIH HHS/United States
- R01 HL157533/HL/NHLBI NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- UL1 RR025780/RR/NCRR NIH HHS/United States
- UL1 TR002535/TR/NCATS NIH HHS/United States
- R01 HL114587/HL/NHLBI NIH HHS/United States
- R01 HL142049/HL/NHLBI NIH HHS/United States
- U01 HL112695/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical